Zhang, Huai; Rios, Rafael S.; Boursier, Jerome et al.
Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry studyCHINESE MEDICAL JOURNAL. Bd. 136. H. 3. 2023 S. 341-350
Franck, Martin; John, Katharina; Al Aoua, Sherin et al.
Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patientsLIVER INTERNATIONAL. 2023
Schleicher, Eva Maria; Kaps, Leonard; Schattenberg, Joern M. et al.
Higher Scores in the Clinical Frailty Scale Are Associated With Covert and Overt Hepatic Encephalopathy in Patients With CirrhosisAMERICAN JOURNAL OF GASTROENTEROLOGY. Bd. 118. H. 9S. 2023 S. S11-S12
Ratziu, Vlad; Ampuero, Javier; Boursier, Jerome et al.
HISTOLOGICAL CLASSIFICATIONS AND PREDICTION OF LIVER- RELATED EVENTS : RESULTS FROM THE MULTICENTRIC, EUROPEAN, HEPATIC OUTCOMES AND SURVIVAL FATTY LIVER REGISTRY ( HOTSURFR) STUDYHEPATOLOGY. Bd. 78. 2023 S. S969-S971
Fichtner, Urs A.; Arslanow, Anita; Binder, Harald et al.
How do (false) positively screened patients experience a screening programme for liver cirrhosis or fibrosis in Germany? A qualitative studyHEALTH EXPECTATIONS. Bd. 26. H. 5. 2023 S. 1923-1930
Koch, Martina; Zecher, Daniel; Lopau, Kai et al.
Human Leucocyte Antigen-Matching Can Improve Long Term Outcome of Renal Allografts from Donors Older Than 75 YearsTRANSPLANTATION PROCEEDINGS. Bd. 55. H. 2. 2023
Kudo, Masatoshi; Finn, Richard S. S.; Galle, Peter R. R. et al.
IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III StudyLIVER CANCER. Bd. 12. H. 3. 2023 S. 238-250
Kudo, Masatoshi; Tsuchiya, Kaoru; Shao, Yu Yun et al.
IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bev in a global phase 3 study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. 2023 S. 538-538
Kudo, Masatoshi; Tsuchiya, Kaoru; Shao, Yu-Yun et al.
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 studyLIVER CANCER. 2023
Vithayathil, Mathew; D'Alessio, Antonio; Fulgenzi, Claudia Angela Maria et al.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinomaHEPATOLOGY INTERNATIONAL. Bd. 17. H. 4. 2023 S. 904-914